HC Wainwright & Co. Initiates Coverage On ZyVersa Therapeutics With Buy Rating, Announces Price Target of $2.5
HC Wainwright & Co. Initiates Coverage On ZyVersa Therapeutics With Buy Rating, Announces Price Target of $2.5
HC Wainwright & Co.以買入評級開始對ZyVersa Therapeutics進行保險,宣佈目標股價爲2.5美元
HC Wainwright & Co. analyst Ed Arce initiates coverage on ZyVersa Therapeutics (NASDAQ:ZVSA) with a Buy rating and announces Price Target of $2.5.
HC Wainwright & Co. 分析師埃德·阿爾塞以買入評級開始對ZyVersa Therapeutics(納斯達克股票代碼:ZVSA)進行報道,並宣佈目標股價爲2.5美元。